|
시장보고서
상품코드
1867535
세계의 세포은행 아웃소싱 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)Cell Banking Outsourcing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 세포은행 아웃소싱에 관한 세계 시장은 2024년에 93억 7,200만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 16.1%로 성장하여 2031년까지 264억 8,500만 달러로 확대될 것으로 예측됩니다.
세포은행 업무의 외주화란 줄기세포, 면역세포, 유전자 조작세포 등의 세포 샘플을 수집, 처리, 증식, 보존하는 중요한 과정을 전문 제3자 서비스 제공업체에 위탁하는 방식을 말합니다. 이 서비스에는 표준화된 GMP 준수 바이오뱅킹 절차, 엄격한 품질 관리, 라이프사이클 전반에 걸친 데이터 추적성이 포함됩니다. 정밀의료, 세포치료, 바이오의약품 연구개발의 급속한 확대에 따라 아웃소싱된 세포은행은 임상연구에서 상업적 적용으로 이어지는 가교역할을 하며 전 세계 의료 및 생명과학 산업 전반에 걸쳐 필수적인 인프라로 자리 잡고 있습니다.
세계 바이오의약품 산업은 구조적 변화의 과정에 있으며, 세포치료, 유전자치료와 같은 새로운 치료법이 대규모 고품질 세포 샘플 뱅킹에 대한 수요 증가를 주도하고 있습니다. 생명공학 기업들은 효율성을 높이고 운영 부담을 줄이기 위해 세포은행, 품질관리(QC), 보관업무를 GMP 또는 ISO 인증을 받은 전문업체에 아웃소싱하는 자산 경량형 R&D 모델을 점점 더 많이 선택하고 있습니다. 한편, 중국, 미국, 한국, 싱가포르 등 각국에서는 국가 정책적으로 세포은행을 전략적 인프라 구축의 중점 분야로 계속 선정하고 있습니다. 이러한 요인들이 복합적으로 작용하여 세포은행 아웃소싱 시장은 급성장 궤도에 올라섰고, 중요한 기반 서비스로서 자본과 업계의 주목을 받고 있습니다. 그러나 수요가 견고함에도 불구하고 이 분야는 큰 장벽에 직면해 있습니다. 특히 시료의 국경 간 이동, 윤리 심사, 데이터 주권 등의 분야에서 세계 규제 격차가 컴플라이언스의 복잡성을 야기하고 있습니다. 이 산업은 진입장벽이 높고, 인프라, 인증된 인력, 품질시스템에 대한 막대한 투자가 필요합니다. 데이터 무결성, 생물학적 안전성, 장기 보관 신뢰성에 대한 고객의 기대가 높아지면서 시장의 통합이 진행되고 있습니다. 그 결과, 주요 업체들은 입지를 강화하는 반면, 중소 업체들은 운영 및 경쟁 압력이 증가하고 있습니다. 수요는 초기 단계의 학술 및 연구용에서 후기 단계 및 상업적 임상 프로그램, 특히 CAR-T 치료, iPS 세포 기반 재생의료, 개인 맞춤형 면역 치료로 이동하고 있습니다. Phase III 이상의 시험에서는 보다 엄격한 시료 취급 및 보관 프로토콜이 요구됩니다. 또한, 세계 제약사 및 CRO/CMO 기업들은 공급망 재구축을 추진하고 있으며, 다중 거점 수집, 지역별 바이오뱅킹, 실시간 디지털 추적성 시스템 도입을 추진하고 있습니다. 빠르게 성숙해가는 상황에서 통합, 자동화, 완전 컴플라이언스 대응 서비스를 제공하는 업체가 우위를 점할 것이며, 플랫폼 중심적이고 생태계를 선도하는 주요 업체로 부상할 것입니다.
이 보고서는 세계 세포은행 아웃소싱 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
셀뱅킹 아웃소싱 시장 규모, 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 위치를 분석하고, 셀뱅킹 아웃소싱에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- SGS Life Sciences
- Lonza
- CCBC
- Vcanbio
- AMAG Pharmaceuticals
- ViaCord
- Thermo Fisher
- Wuxi Apptec
- CordLife
- Esperite
- Reliance Life Sciences
- Lifecell
- Cryo-Cell
- Toxikon
- Goodwin Biotechnology
- Texcell
- Cryo Stemcell
유형별 부문
- 줄기세포 은행
- 비줄기세포 은행
용도별 부문
- 세포은행 보관
- 은행 특성 평가 및 시험
- 세포은행 준비
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Cell Banking Outsourcing was estimated to be worth US$ 9372 million in 2024 and is forecast to a readjusted size of US$ 26485 million by 2031 with a CAGR of 16.1% during the forecast period 2025-2031.
Cell Banking Outsourcing refers to the practice of delegating the critical processes of collecting, processing, expanding, and storing cell samples-such as stem cells, immune cells, or genetically engineered cells-to specialized third-party service providers. This service involves standardized GMP-compliant biobanking procedures, stringent quality control, and full lifecycle data traceability. With the rapid expansion of precision medicine, cell therapies, and biopharmaceutical R&D, outsourced cell banking is becoming a vital infrastructure across the global healthcare and life sciences industries, bridging the gap from clinical research to commercial application.
The global biopharmaceutical sector is undergoing structural transformation, with emerging therapies such as cell and gene therapy driving a surge in demand for large-scale, high-quality cell sample banking. Biotech companies are increasingly favoring asset-light R&D models, outsourcing cell banking, QC, and storage to specialized providers with GMP or ISO certifications to enhance efficiency and reduce operational burden. Meanwhile, national policies in countries like China, the U.S., South Korea, and Singapore continue to prioritize cell banking as a strategic infrastructure initiative. These factors jointly propel the Cell Banking Outsourcing market into a high-growth trajectory, attracting both capital and industry attention as a critical enabling service. Despite strong demand, the sector faces considerable hurdles. Global disparities in regulation-especially in areas such as sample cross-border transfer, ethical approvals, and data sovereignty-present compliance complexities. The industry has high entry barriers, requiring significant investment in infrastructure, certified personnel, and quality systems. Client expectations around data integrity, biosafety, and long-term storage reliability are also rising, leading to market consolidation. As a result, while leading providers strengthen their positions, smaller players face increasing operational and competitive pressures.Demand is shifting from early-stage academic and research applications to late-phase and commercial clinical programs, especially in CAR-T, iPSC-based regenerative therapies, and personalized immunotherapies. Phase III+ trials require stricter sample handling and storage protocols. Additionally, global pharma and CRO/CMO players are reshaping their supply chains, driving the adoption of multi-site collection, regionalized biobanking, and real-time digital traceability systems. The future will favor providers offering integrated, automated, and fully compliant services-emerging as platform-centric and ecosystem-leading companies in a rapidly maturing landscape.
This report aims to provide a comprehensive presentation of the global market for Cell Banking Outsourcing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cell Banking Outsourcing by region & country, by Type, and by Application.
The Cell Banking Outsourcing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell Banking Outsourcing.
Market Segmentation
By Company
- SGS Life Sciences
- Lonza
- CCBC
- Vcanbio
- AMAG Pharmaceuticals
- ViaCord
- Thermo Fisher
- Wuxi Apptec
- CordLife
- Esperite
- Reliance Life Sciences
- Lifecell
- Cryo-Cell
- Toxikon
- Goodwin Biotechnology
- Texcell
- Cryo Stemcell
Segment by Type
- Stem Cell Banking
- Non-stem Cell Banking
Segment by Application
- Cell Bank Storage
- Bank Characterization and Testing
- Cell Bank Preparation
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cell Banking Outsourcing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cell Banking Outsourcing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cell Banking Outsourcing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Cell Banking Outsourcing Product Introduction
- 1.2 Global Cell Banking Outsourcing Market Size Forecast (2020-2031)
- 1.3 Cell Banking Outsourcing Market Trends & Drivers
- 1.3.1 Cell Banking Outsourcing Industry Trends
- 1.3.2 Cell Banking Outsourcing Market Drivers & Opportunity
- 1.3.3 Cell Banking Outsourcing Market Challenges
- 1.3.4 Cell Banking Outsourcing Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Cell Banking Outsourcing Players Revenue Ranking (2024)
- 2.2 Global Cell Banking Outsourcing Revenue by Company (2020-2025)
- 2.3 Key Companies Cell Banking Outsourcing Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Cell Banking Outsourcing Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Cell Banking Outsourcing
- 2.6 Cell Banking Outsourcing Market Competitive Analysis
- 2.6.1 Cell Banking Outsourcing Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Cell Banking Outsourcing Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell Banking Outsourcing as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Stem Cell Banking
- 3.1.2 Non-stem Cell Banking
- 3.2 Global Cell Banking Outsourcing Sales Value by Type
- 3.2.1 Global Cell Banking Outsourcing Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Cell Banking Outsourcing Sales Value, by Type (2020-2031)
- 3.2.3 Global Cell Banking Outsourcing Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Cell Bank Storage
- 4.1.2 Bank Characterization and Testing
- 4.1.3 Cell Bank Preparation
- 4.2 Global Cell Banking Outsourcing Sales Value by Application
- 4.2.1 Global Cell Banking Outsourcing Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Cell Banking Outsourcing Sales Value, by Application (2020-2031)
- 4.2.3 Global Cell Banking Outsourcing Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Cell Banking Outsourcing Sales Value by Region
- 5.1.1 Global Cell Banking Outsourcing Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Cell Banking Outsourcing Sales Value by Region (2020-2025)
- 5.1.3 Global Cell Banking Outsourcing Sales Value by Region (2026-2031)
- 5.1.4 Global Cell Banking Outsourcing Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Cell Banking Outsourcing Sales Value, 2020-2031
- 5.2.2 North America Cell Banking Outsourcing Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Cell Banking Outsourcing Sales Value, 2020-2031
- 5.3.2 Europe Cell Banking Outsourcing Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Cell Banking Outsourcing Sales Value, 2020-2031
- 5.4.2 Asia Pacific Cell Banking Outsourcing Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Cell Banking Outsourcing Sales Value, 2020-2031
- 5.5.2 South America Cell Banking Outsourcing Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Cell Banking Outsourcing Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Cell Banking Outsourcing Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Cell Banking Outsourcing Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Cell Banking Outsourcing Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Cell Banking Outsourcing Sales Value, 2020-2031
- 6.3.2 United States Cell Banking Outsourcing Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Cell Banking Outsourcing Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Cell Banking Outsourcing Sales Value, 2020-2031
- 6.4.2 Europe Cell Banking Outsourcing Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Cell Banking Outsourcing Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Cell Banking Outsourcing Sales Value, 2020-2031
- 6.5.2 China Cell Banking Outsourcing Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Cell Banking Outsourcing Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Cell Banking Outsourcing Sales Value, 2020-2031
- 6.6.2 Japan Cell Banking Outsourcing Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Cell Banking Outsourcing Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Cell Banking Outsourcing Sales Value, 2020-2031
- 6.7.2 South Korea Cell Banking Outsourcing Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Cell Banking Outsourcing Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Cell Banking Outsourcing Sales Value, 2020-2031
- 6.8.2 Southeast Asia Cell Banking Outsourcing Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Cell Banking Outsourcing Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Cell Banking Outsourcing Sales Value, 2020-2031
- 6.9.2 India Cell Banking Outsourcing Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Cell Banking Outsourcing Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 SGS Life Sciences
- 7.1.1 SGS Life Sciences Profile
- 7.1.2 SGS Life Sciences Main Business
- 7.1.3 SGS Life Sciences Cell Banking Outsourcing Products, Services and Solutions
- 7.1.4 SGS Life Sciences Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.1.5 SGS Life Sciences Recent Developments
- 7.2 Lonza
- 7.2.1 Lonza Profile
- 7.2.2 Lonza Main Business
- 7.2.3 Lonza Cell Banking Outsourcing Products, Services and Solutions
- 7.2.4 Lonza Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.2.5 Lonza Recent Developments
- 7.3 CCBC
- 7.3.1 CCBC Profile
- 7.3.2 CCBC Main Business
- 7.3.3 CCBC Cell Banking Outsourcing Products, Services and Solutions
- 7.3.4 CCBC Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.3.5 CCBC Recent Developments
- 7.4 Vcanbio
- 7.4.1 Vcanbio Profile
- 7.4.2 Vcanbio Main Business
- 7.4.3 Vcanbio Cell Banking Outsourcing Products, Services and Solutions
- 7.4.4 Vcanbio Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.4.5 Vcanbio Recent Developments
- 7.5 AMAG Pharmaceuticals
- 7.5.1 AMAG Pharmaceuticals Profile
- 7.5.2 AMAG Pharmaceuticals Main Business
- 7.5.3 AMAG Pharmaceuticals Cell Banking Outsourcing Products, Services and Solutions
- 7.5.4 AMAG Pharmaceuticals Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.5.5 AMAG Pharmaceuticals Recent Developments
- 7.6 ViaCord
- 7.6.1 ViaCord Profile
- 7.6.2 ViaCord Main Business
- 7.6.3 ViaCord Cell Banking Outsourcing Products, Services and Solutions
- 7.6.4 ViaCord Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.6.5 ViaCord Recent Developments
- 7.7 Thermo Fisher
- 7.7.1 Thermo Fisher Profile
- 7.7.2 Thermo Fisher Main Business
- 7.7.3 Thermo Fisher Cell Banking Outsourcing Products, Services and Solutions
- 7.7.4 Thermo Fisher Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.7.5 Thermo Fisher Recent Developments
- 7.8 Wuxi Apptec
- 7.8.1 Wuxi Apptec Profile
- 7.8.2 Wuxi Apptec Main Business
- 7.8.3 Wuxi Apptec Cell Banking Outsourcing Products, Services and Solutions
- 7.8.4 Wuxi Apptec Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.8.5 Wuxi Apptec Recent Developments
- 7.9 CordLife
- 7.9.1 CordLife Profile
- 7.9.2 CordLife Main Business
- 7.9.3 CordLife Cell Banking Outsourcing Products, Services and Solutions
- 7.9.4 CordLife Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.9.5 CordLife Recent Developments
- 7.10 Esperite
- 7.10.1 Esperite Profile
- 7.10.2 Esperite Main Business
- 7.10.3 Esperite Cell Banking Outsourcing Products, Services and Solutions
- 7.10.4 Esperite Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.10.5 Esperite Recent Developments
- 7.11 Reliance Life Sciences
- 7.11.1 Reliance Life Sciences Profile
- 7.11.2 Reliance Life Sciences Main Business
- 7.11.3 Reliance Life Sciences Cell Banking Outsourcing Products, Services and Solutions
- 7.11.4 Reliance Life Sciences Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.11.5 Reliance Life Sciences Recent Developments
- 7.12 Lifecell
- 7.12.1 Lifecell Profile
- 7.12.2 Lifecell Main Business
- 7.12.3 Lifecell Cell Banking Outsourcing Products, Services and Solutions
- 7.12.4 Lifecell Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.12.5 Lifecell Recent Developments
- 7.13 Cryo-Cell
- 7.13.1 Cryo-Cell Profile
- 7.13.2 Cryo-Cell Main Business
- 7.13.3 Cryo-Cell Cell Banking Outsourcing Products, Services and Solutions
- 7.13.4 Cryo-Cell Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.13.5 Cryo-Cell Recent Developments
- 7.14 Toxikon
- 7.14.1 Toxikon Profile
- 7.14.2 Toxikon Main Business
- 7.14.3 Toxikon Cell Banking Outsourcing Products, Services and Solutions
- 7.14.4 Toxikon Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.14.5 Toxikon Recent Developments
- 7.15 Goodwin Biotechnology
- 7.15.1 Goodwin Biotechnology Profile
- 7.15.2 Goodwin Biotechnology Main Business
- 7.15.3 Goodwin Biotechnology Cell Banking Outsourcing Products, Services and Solutions
- 7.15.4 Goodwin Biotechnology Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.15.5 Goodwin Biotechnology Recent Developments
- 7.16 Texcell
- 7.16.1 Texcell Profile
- 7.16.2 Texcell Main Business
- 7.16.3 Texcell Cell Banking Outsourcing Products, Services and Solutions
- 7.16.4 Texcell Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.16.5 Texcell Recent Developments
- 7.17 Cryo Stemcell
- 7.17.1 Cryo Stemcell Profile
- 7.17.2 Cryo Stemcell Main Business
- 7.17.3 Cryo Stemcell Cell Banking Outsourcing Products, Services and Solutions
- 7.17.4 Cryo Stemcell Cell Banking Outsourcing Revenue (US$ Million) & (2020-2025)
- 7.17.5 Cryo Stemcell Recent Developments
8 Industry Chain Analysis
- 8.1 Cell Banking Outsourcing Industrial Chain
- 8.2 Cell Banking Outsourcing Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Cell Banking Outsourcing Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Cell Banking Outsourcing Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
